Capricor Therapeutics (CAPR) saw its stock soar 5.04% on Wednesday, following news that the European Medicines Agency (EMA) has granted both Orphan Drug and Advanced Therapy Medicinal Product (ATMP) designations to its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD).
The Orphan Drug designation provides Capricor with several benefits in Europe, including 10 years of market exclusivity if deramiocel is approved, as well as reduced regulatory fees. The ATMP designation offers regulatory support to assist in the development of cell-based therapies like deramiocel, potentially reducing time to market and streamlining the development process.
Capricor's CEO Linda Marban expressed excitement about these designations, stating they are significant steps forward in bringing deramiocel to DMD patients worldwide. The company also announced it has initiated a rolling Biologics License Application (BLA) with the U.S. FDA and expects to complete the submission by the end of 2024, seeking full approval for deramiocel to treat DMD-cardiomyopathy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。